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 BACKGROUND: Urinary trypsin inhibitor (UTI, ulinastatin 
®) inhibits proteinases and has been used for the treatment 
of ulcerative colitis (UC). We investigated the therapeutic 
effect of UTI in patients with UC and correlated this effect 
to mast cell (MC) and macrophages (M) counts in the 
colonic mucosal wall. 
 DESIGN: Patients with UC resistant to corticosteroids 
(n=16) and normal control subjects (n=10) were included 
in this study. Biopsy specimens obtained from the sigmoid 
colon of patients before and after UTI therapy were immu-
nostained with antibodies to tryptase (AA1, MC) and CD68 
(M). The number of MC and M in the lamina propria (LP) 
was determined and expressed per mm2 of LP. 
 RESULTS: Nine patients with UC responded to UTI treat-
ment. The mean number of MC in the upper part of LP in
responders(440±51/mm2)was　 higher　 than　 nonresponders
(312±76/mm2)and　 normal　 controls(200±47/mm2).　 MC
counts in the lower part of the LP were not different in re-
sponders and nonresponders, although the counts in both 
groups were significantly higher than control. The number 
of M in the lower part of LP was similar in responders and 
nonresponders, but were higher than control subjects. M 
counts in the upper part of LP were similar in both groups 
of patients and control. Effective treatment with UTI in re-
sponders was associated with a significant fall in the num-
ber of MC in the upper layer of LP but not in M. 
 CONCLUSION. Our results showed that UTI is an effec-
tive therapy in steroid-resistant UC. Our results also showed 
effective therapy with UTI was associated with a reduction 
in MC counts in the colonic mucosa, suggesting that the 
control of these cells may mediate, at least in part, the 
therapeutic effects of UTI in UC.
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Introduction
 Corticosteroids are effective in bringing about a 
clinical remission in patients with ulcerative colitis 
(UC).1'2' In some cases, however, they are not always 
effective even when used at a high dose."" Urinary 
trypsin inhibitor (UTI) has been used in steroid-resis-
tant UC.5.6) UTI is a potential inhibitor of proteinases, 
including neutrophil elastase, trypsin, plasmin, and 
cathepsin B and H, and has been used for the treat-
ment of experimental and clinical acute pancreatitis, 
septic shock, and UC.5 " However, its pharmacological 
and pathological effects in UC have not been eluci-
dated. 
 Mast cells and macrophages are potent source of in-
flammatory mediators and are widely distributed 
throughout the gastrointestinal mucosa.12,"1 The func-
tion of these two cells seems not to be restricted to in-
flammatory process. Recent studies have shown that 
both cell types can also produce regulatory and 
immunemodulating mediators and cytokines in inflam-
matory bowel diseases as well as other chronic inflam-
matory conditions.",") In this regard, the exact role of 
the mast cells in UC has not been clearly defined. 
While some investigators have suggested that these 
cells may influence the course of UC,16,17) others con-
cluded that there is no relationship between mast cells 
and UC.18.19> 
 In the present study, we examined the effect of UTI 
in UC resistant to corticosteroids. We also compared 
mast cell and macrophage counts before and after UTI 
therapy in patients with UC who responded to UTI 
and those who failed to respond to UTI.
Methods
Patients 
  The study was carried. out between January 1992 
and December 1997 in Nagasaki University Hospital. 
Sixteen patients with UC who were resistant to a stan-
dard medical therapy (corticosteroid with or without 
oral sulfasalazine) were enrolled in the study. We also 
examined 10 control patients who did not have UC 
and were not treated with anti-UC medications. The 
characteristics of these patients are summarized in 
Table 1. The diagnosis of UC was based on typical 
symptoms, radiographic and endoscopic findings. To 
classify patients as treatment-resistant or treatment-
sensitive retrospectively, we modified the definition 
outlined in the Working Term report on medical treat-
ment regimens at accepted therapeutic doses.21 We de-
fined effective response to therapy as a decrease in 
disease activity score of 2 or more points. Clinical dis-
ease activity of UC was determined by Truelove's cri-
teria." Patients were treated by intravenous injections 
of 200,000 unit UTI weekly for three months. Total 
scores were evaluated at wk 2 and 4 wk after com-
mencement of UTI therapy.
Tissue samples 
 At least two biopsy specimens from UC patients be-
fore and after UTI therapy were obtained from the 
sigmoid colon from each patient during colonoscopy. 
The study protocol was approved by the Human 
Ethics Review Committees of Nagasaki University and 
a signed consent form was obtained from each subject. 
The tissue samples were fixed with buffered formalin, 
embedded in paraffin, and cut into 5 u m sections.
Immunohistochemistry 
 For immunohistochemical staining of the tissue sam-
ple, each section was initially treated for 30 minutes 
with methanol containing 0.3% H2O2 to quench en-
dogenous peroxidase activity. Thereafter, non-specific 
binding sites were blocked by incubation with 10% nor-
mal rabbit serum (NRS) for 20 minutes. In the next 
step, the primary antibody, either mouse monoclonal 
anti-human mast cell tryptase, AA 1, 1:1000 (Dako Co., 
Tokyo, Japan) or mouse monoclonal anti-human, 
macrophage, CD68, PG-M1 1:500 (Dako), diluted in PBS, 
was applied overnight in a sealed humidity chamber. 
After washing with PBS, the bound antibody was de-
tected by the M-kit (Nichirei, Tokyo), as described 
previously by Sarin et al.20~
Macrophage and mast cell counts 
  Slides were coded and mast cell and macrophage 
counts were determined by one investigator (YN) who 
was blind to the clinical and histological diagnoses. 
Sections were examined at a high magnification ( X 
400). Mast cells and macrophages located in the lam-
ina propria by dividing two equal parts, upper layer, 
and lower layer of lamina propria, were counted 
within the test area of a calibrated ocular grid in ten 
contiguous non-overlapping fields in each section. We 
also determined the area fraction of lamina propria by 
point counting. Mast cell and macrophage counts were 
expressed as cell numbers/mm' of lamina propria.
Statistical analysis 
 Data were expressed as mean ± SD. Differences in 
mast cell and macrophage counts between UC and 
control were examined for statistical significance using 
ANOVA and Student's t-test. A p value < 0.05 denoted 
the presence of a significant difference.
Results
Response to UTI therapy 
 Clinically, two patients had severe and 14 moderate 
UC activity before UTI treatment. Seven patients 
(44%) did not respond to UTI; three of them were ul-
timately treated by total colectomy. The other nine 
(64%) patients responded to therapy, particularly in 
one patient in whom the treatment showed a remark-
able effect. There were no serious adverse effects that 
required discontinuation of therapy. Furthermore, there 
were no significant differences between responders and 
non-responders with regard to age, sex, and endoscopic 
severity of colonic abnormalities or UC disease activity 
except for the duration of UC (Table 1).
Table 1. Characteristics of patients with ulcerative colitis (UC).
                         Ulcerative colitis Control 
                        Responders Non-responders 
Number 9 7 10 
Age (years)* 36±18 36± 19 41±1.4 
Sex MY 6:3 5:2 7:3 
Duration of UC (years)' 3.0±1.7 6.3±9.09 -
Endoscopic extent of UC 
   left side colitis 2 1 -
   pancolitis 7 6 -
Disease activity 
   moderate 8 6 -
   severe 1 1 -
Treatment 
   steroids 8 7 -
   sulfasalazine 9 7 -
*Data are mean ± SD
, 9 p < 0.05 compared to responders
Mast cell and macrophage counts before UTI therapy 
  Immunostaining of the colonic mucosa showed that 
in control subjects, the number of AA1-positive mast 
cells in the lower layer of the lamina propria was 
higher than in the upper layer (Fig. 1A). In contrast, 
the distribution of mast cells in the lower and upper 
parts of the lamina propria was similar in patients 
with UC (Fig. 113). The number of mast cells in the 
upper layer of lamina propria in responders was sig-
nificantly higher than their number in the correspond-
ing region of nonresponders and control subjects (Fig. 
2, Table 2). However, there were no significant differ-
ences in the number of mast cells present in the lower 
part of the lamina propria between responders and
nonresponders. Mast cell counts in both groups of UC 
patients was higher than in normal controls (Fig. 2). 
There were no significant differences in the number of 
macrophages present in the lower part of the lamina 
propria between responders and nonresponders, but 
both counts were higher than in control subjects (Fig. 
2). There was no significant difference in macrophage 
counts in the upper layer of the lamina propria among 
the three groups (Fig. 2).
Fig. 2. The number of mast cells and macrophages in lamina 
propria
Table 2. The number of mast cells & macrophages in the 
colonic mucosa before UTI therapy
                     Mast cells (/mm2) Macrophages (/mm2) 
                        upper lower upper lower
Ulcerative colitis 
   Treatment sensitive 440±51* 429±64 481±60 460±40 
          (n=5) 
   Treatment resistant 312±76 392±66 460±34 424±67 
         (n=5) 
Normal control(n=10) 200±47 280±61 406±31 260± 52
*P < 0 .05, compared with the treatment resistant patients. 
Data are mean ± SD.
Fig. 1. Representative sections of the colonic mucosa stained 
for AA1. A: Note the high number of AA1-positive cells in 
the lower part of the lamina propria than in the upper part 
in the mucosa of the normal colon. B: The distribution of 
AA1-positive cells in ulcerative colitis in the lower part is 
similar to that in the upper part of the lamina propria. 
Magnification X 400.
Mast cell and macrophage counts after UTI therapy 
 We also examined biopsies obtained after UTI ther-
apy in four responders and compared mast cell and 
macrophage counts to those before therapy. UTI treat-
ment resulted in a significant reduction in the number 
of mast cells in the upper layer of the lamina propria 
from 423±40 to 299±86 cell/mm2 (p < 0.05). While 
UTI therapy also decreased the number of mast cells
in the lower layer, the change was not statistically sig-
nificant (Fig. 3, Table 3). UTI treatment did not pro-
duce a significant change in macrophage counts in 
both layers of the lamina propria (Fig. 3).
Fig. 3. The number of mast cells and macrophages in lamina 
propria
Table 3. The number of mast cells & macrophages in the 
colonic mucosa after UTI therapy
                      Mast cells (/mm2) Macrophages (/mm2) 
                        upper lower upper lower
Treatment sensitive 
      Ulcerative colitis 
   Treatment sensitive 423±40* 442± 66 481±69 465± 46 
   Treatment resistant 299±86 335±113 455±53 390±102
*P < 0 .05, compared with the post treatment patients. 
Data are mean ± SD.
Discussion
 UTI is a unique trypsin inhibitor purified from 
human urine.21.22' It exerts a membrane stabilization ac-
tion on leukocytes and macrophages and protects 
against free radical-induced lipid peroxidation...... > Mast 
cells and macrophages are known to produce several 
inflammatory mediators such as histamine, prostaglan-
din, and cytokines.1315' Minocha et al."' and Higa et al.24' 
suggested that mast cells are not crucial for the devel-
opment of experimental colitis in mice. Compared to 
the normal pattern, the number of mast cells in the in-
testinal mucosa of patients with UC has been reported 
to be higher in some studies,25.26' similar," 20' or lower in
others.'"') These discrepancies may be due to de-
granulation of mast cells in the colonic mucosa; since 
such cells do not stain by mast cell stains."' However, 
the presence of high mast cell counts in UC have been 
reported in more recent studies that employed 
immunostaining for tryptase.16,11) 
 Glucocorticoids are the most effective agents for the 
treatment of severe UC, but the exact mechanism of 
action of these potent drugs remains unknown.2i' In 
this regard, Shimada et al.') reported recently that 
nonresponders to glucocorticoid therapy show a sig-
nificant increase both in the number of glucocorticoid 
binding sites and in apparent dissociation contact com-
pared with responders.') However, UTI does not bind 
to glucocorticoid receptors, even when the number of 
these receptors is increased.28' 
 Mast cells are thought to have a protective effect in 
the mucosa by enhancing epithelial repair .21) Further-
more, the mast cell protease, tryptase, enhances inter-
leukin (IL)-8 release.",") Increased number of mast cells 
in colonic wall may protect the mucosa by limiting 
the spread of inflammation.") Goldsmith and cowork-
ers 2" reported a significant reduction in mast cell 
counts in patients with inflammatory bowel disease 
(IBD) treated with corticosteroids compared with con-
trol patients and patients with IBD who were not 
treated with corticosteroids. Our data also demon-
strated that UTI significantly reduced mast cell popu-
lation, particularly those in the upper layer of the lam-
ina propria (Fig. 3). 
 A low molecular weight serine protease inhibitor, 
named trypstatin, which has a high degree of sequence 
homology with UTI, markedly inhibits tryptase in rat 
mast cell.") King et al. 16) reported a protective effect 
for mast cells in patients with UC and that 69% of pa-
tients in remission have high mast cell counts in the 
colonic mucosa.16' Trypstatin has a high degree of se-
quence homology with human and bovine inter-alpha-
trypsin inhibitor.32.33> Mast cells are often seen degra-
nulated in areas of active disease, suggesting that the 
inflammatory mediators released from these cells con-
tribute to the pathophysiology of these disorders.33' 
Accumulation of mast cells at the visible line of de-
marcation between normal and abnormal mucosa sug-
gests that these cells may play a critical role in either 
accelerating the process of inflammation or in sup-
pressing continued extension of the disease.]" 
 Resistance to steroid therapy in patients with UC is 
probably due to several factors. These include long du-
ration of disease activity and presence of perinuclear 
antineutrophil cytoplasmic antibodies (pANCA),34) 
Sandborn et al.35' postulated that the increased fre-
quency of pANCA in treatment-resistant left-sided UC
may reflect a possible association between these anti-
bodies and relative resistance to medical therapy in 
patients with UC. 
 In conclusion, our data showed that UTI can be ef-
fective in steroid-resistant patients with UC. To our 
knowledge, this is the first study reporting a correla-
tion between UTI therapy and colonic mast cell counts. 
Our data suggest that the number of mast cells in the 
upper part of the lamina propria in patients with UC 
may be a useful marker for a positive response to UTI 
therapy. Further studies are necessary to investigate 
the interaction between UTI and inflammatory cells in 
the colonic mucosa.
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